title: Chemopreventive activity of a C-glucuronide analog of N-(4-hydroxyphenyl) retinamide-O-glucuronide against mammary tumor development and growth.
abstract: The long term chemopreventive effects of the N-(4-hydroxyphenyl) retinamide-O-glucuronide (4-HPROG), and its stable C-linked benzyl glucuronide analog, retinamidobenzyl glucuronide (4-HPRCG) on the growth and development of 7,12-dimethylbenz[a]anthracene-induced mammary tumors were compared. The retinamidobenzyl glucuronide is stable toward acid hydrolysis and resists the actions of beta-glucuronidase. The results indicate that the C-linked glucuronide analog, 4-HPRCG has a greater chemopreventive potency than an equimolar concentration of 4-HPROG. Tumor latency was 15% longer in rats fed 2 mmol/kg diet of 4-HPRCG as compared to 4-HPROG. At 80 days post DMBA-intubation, tumor incidence was 57% and 27% in the 4-HPROG and 4-HPRCG treated rats, respectively. Tumor multiplicity was also markedly decreased in the 4-HPRCG treated rats. At 80 days post DMBA intubation the control rats had an average of 1.43 tumors/rat compared to 0.71 and 0.36 tumors/rat in the 4-HPROG and 4-HPRCG respectively. The higher potency and low toxicity of 4-HPRCG suggest that this stable analog may have an in vivo chemopreventive advantage over its analog, 4-HPROG. The results also demonstrated that these glucuronide analogs do not bind effectively in vitro either to the nuclear retinoid receptors or to the cellular retinoid binding proteins. Regardless of the mode of action of these retinoids, they are clearly effective chemopreventive agents.
authors.affiliation: Department of Surgery, Ohio State University, Columbus 43210, USA.
authors.forename: H M
authors.initials: HM
authors.lastname: Abou-Issa
authors.forename: G A
authors.initials: GA
authors.lastname: Alshafie
authors.forename: R W
authors.initials: RW
authors.lastname: Curley
authors.forename: M F
authors.initials: MF
authors.lastname: Wong
authors.forename: M
authors.initials: M
authors.lastname: Clagett-Dame
authors.forename: J J
authors.initials: JJ
authors.lastname: Repa
authors.forename: V
authors.initials: V
authors.lastname: Sikri
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D005260:Female; D017313:Fenretinide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005965:Glucuronates / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012176:Retinoids / Q000627:therapeutic use*
chemical_list: D016588:Anticarcinogenic Agents; D005965:Glucuronates; C084238:N-((4-hydroxyphenyl)retinamide)-O-glucuronide; D012176:Retinoids; C119692:retinamidobenzyl glucuronide; D017313:Fenretinide; D015127:9,10-Dimethyl-1,2-benzanthracene